By Devika Patel
Knoxville, Tenn., Nov. 30 - ReNeuron Group plc said it arranged a two-year committed equity funding facility with Matrix Corporate Capital LLP for £5 million. The facility may be increased.
Proceeds will be used for working capital.
Based in Guildford, England, ReNeuron develops adult stem cell therapies.
| Issuer: | ReNeuron Group plc
|
| Issue: | Equity funding facility
|
| Amount: | £5 million
|
| Tenor: | Two years
|
| Warrants: | No
|
| Investor: | Matrix Corporate Capital LLP
|
| Pricing date: | Nov. 30
|
| Stock symbol: | London: RENE
|
| Stock price: | 6.29p at close Nov. 30
|
| Market capitalization: | £21.5 million
|
© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere.
For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.
